Zhou Yaxian, Liao Yaxian, Zhao Yuan, Tang Weiping
Lachman Institute of Pharmaceutical Development, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, 53705, USA.
Department of Chemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA.
ChemMedChem. 2024 Dec 16;19(24):e202300643. doi: 10.1002/cmdc.202300643. Epub 2024 Oct 29.
The emerging of lysosomal targeting chimera (LYTAC) expands the field of targeted protein degradation (TPD) to include the extracellular proteins for precise depletion. However, most of the reported LYTACs either induce ubiquitous degradation of the protein of interest (POI) in a broad range of tissues or specifically target liver cells. More tissue-selective degraders are highly desirable. Herein, we describe the development of cyclic RGD (cRGD) peptide-antibody conjugates as a novel class of integrin targeting chimeras (ITACs) with potential cancer selectivity. Our results indicate that the ITACs are able to recruit integrin to induce the degradation of both soluble and membrane targets in the lysosome. We observed higher efficiency of ITACs on degrading membrane protein in cancer cells, providing a promising platform for cancer-selective TPD strategy.
溶酶体靶向嵌合体(LYTAC)的出现将靶向蛋白质降解(TPD)领域扩展到包括细胞外蛋白,以实现精确清除。然而,大多数已报道的LYTACs要么在广泛的组织中诱导目的蛋白(POI)的普遍降解,要么特异性靶向肝细胞。非常需要更多具有组织选择性的降解剂。在此,我们描述了环状RGD(cRGD)肽-抗体缀合物作为一类新型整合素靶向嵌合体(ITACs)的开发,其具有潜在的癌症选择性。我们的结果表明,ITACs能够募集整合素以诱导溶酶体中可溶性和膜靶标的降解。我们观察到ITACs在癌细胞中降解膜蛋白的效率更高,为癌症选择性TPD策略提供了一个有前景的平台。